THNR

THNR focuses on the weight loss industry. The fund tracks an index that invests in companies involved in manufacturing and enabling GLP-1 agonist pharmaceutical businesses. GLP-1 agonists seek to lower blood sugar levels, reduce appetite, and promote fullness, with the ultimate potential for weight loss. Starting with an initial universe of companies from the developed markets, the index selects:1) 'drug manufacturers', which are firms with GLP-1 agonist drugs that either have been launched or are currently in Food and Drug Administration (FDA) clinical trials, and 2) 'enablers', which are companies engaged in the outsourced development and manufacturing, as well as the production and distribution of GLP-1 agonist drugs. Drug manufacturers comprise 70% of the portfolio, while enablers cover the remaining 30%. Holdings within each segment are market cap-weighted, subject to individual security capping. The index reconstitutes and rebalances quarterly.